Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
Objective: Glucagon-like peptide-1 and glucagon receptor (GLP-1R/GCGR) co-agonism can maximise weight loss and improve glycaemic control in type 2 diabetes and obesity. In this study, we investigated the cellular and metabolic effects of modulating the balance between G protein and β-arrestin-2 recr...
Saved in:
Main Authors: | Phil Pickford (Author), Maria Lucey (Author), Roxana-Maria Rujan (Author), Emma Rose McGlone (Author), Stavroula Bitsi (Author), Fiona B. Ashford (Author), Ivan R. Corrêa (Author), David J. Hodson (Author), Alejandra Tomas (Author), Giuseppe Deganutti (Author), Christopher A. Reynolds (Author), Bryn M. Owen (Author), Tricia M. Tan (Author), James Minnion (Author), Ben Jones (Author), Stephen R. Bloom (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients
by: Thomas Monfeuga, et al.
Published: (2024) -
Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
by: Samantha L. Price, MRes, et al.
Published: (2015) -
Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
by: Nazi Song, et al.
Published: (2022) -
Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
by: Maria Lucey, et al.
Published: (2020) -
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
by: Tina Zimmermann, et al.
Published: (2022)